U.S. markets open in 4 hours 41 minutes
  • S&P Futures

    4,067.50
    +62.75 (+1.57%)
     
  • Dow Futures

    32,549.00
    +390.00 (+1.21%)
     
  • Nasdaq Futures

    12,496.25
    +251.50 (+2.05%)
     
  • Russell 2000 Futures

    1,813.90
    +31.50 (+1.77%)
     
  • Crude Oil

    114.24
    +0.04 (+0.04%)
     
  • Gold

    1,823.40
    +9.40 (+0.52%)
     
  • Silver

    21.68
    +0.13 (+0.62%)
     
  • EUR/USD

    1.0493
    +0.0055 (+0.52%)
     
  • 10-Yr Bond

    2.8770
    0.0000 (0.00%)
     
  • Vix

    26.69
    -2.18 (-7.55%)
     
  • GBP/USD

    1.2473
    +0.0149 (+1.21%)
     
  • USD/JPY

    129.3620
    +0.3090 (+0.24%)
     
  • BTC-USD

    30,650.88
    +849.38 (+2.85%)
     
  • CMC Crypto 200

    687.94
    +445.26 (+183.48%)
     
  • FTSE 100

    7,516.38
    +51.58 (+0.69%)
     
  • Nikkei 225

    26,659.75
    +112.70 (+0.42%)
     

No Increased Risk Of Blood Clots After Second Dose Of AstraZeneca's COVID-19 Shot, Study Shows

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

A person's risk of blood clots does not increase after the second Oxford/AstraZeneca plc (NASDAQ: AZN) COVID-19 vaccine shot. The Company is trying to boost confidence in its jab, which has taken a beating after reports of rare but serious blood clotting events after vaccination.

  • The study led and funded by AstraZeneca could boost people's confidence in receiving their second dose.

  • The research, published in the Lancet, shows that the rates of the very rare clotting disorder, thrombosis with thrombocytopenia syndrome (TTS), following a second dose are comparable to those among the unvaccinated population.

  • The estimated rate of the rare clotting disorder after the second AstraZeneca shot was 2.3 per million people vaccinated.

  • From AstraZeneca's global safety database, the data captured reported cases of TTS in the 14 days after receiving the first or second dose through the end of April 2021, covering some 5.6 million second doses and 49 million first doses.

  • The data confirmed reports of an elevated risk of TTS in those receiving their first shot, however, which occurred at a rate of 8.1 per million people.

  • The rate was 8.1 per million vaccines after the first dose, they said.

  • Price Action: AZN shares are down 0.23% at $57.33 during the market session on the last check Wednesday.

  • Photo by Johaehn from Pixabay

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.